Morgan Stanley Boosts Gilead (GILD) Outlook on Updated Biopharma Models

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 13 NASDAQ Stocks with Highest Dividends.

Morgan Stanley Boosts Gilead (GILD) Outlook on Updated Biopharma Models

On April 10, Morgan Stanley raised the firm’s price recommendation on Gilead Sciences, Inc. (NASDAQ:GILD) to $175 from $171. It kept an Overweight rating on the shares. The firm updated its models across biopharma coverage, reflecting IQVIA trends and intra-quarter updates ahead of Q1 earnings.

For the first quarter of 2026, Gilead Sciences expects about $107 million in acquired IPR&D expenses. This represents a charge of around $0.07 to both GAAP and non-GAAP diluted earnings per share. These expenses can include, in any given quarter, known commitments tied to previously announced collaborations and partnerships. They may also include upfront and other costs linked to new business development activities during the period.

In Q1 2026, the total includes an upfront payment of about $80 million related to the Genhouse collaboration announced on February 13, 2026. This amount was not included in the full-year 2026 IPR&D guidance of $300 million provided on February 10, 2026.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company focused on developing treatments for serious diseases. Its work spans areas such as HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company focuses on discovering, developing, and delivering medicines to address unmet needs across virology, oncology, and other therapeutic areas.

While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Blue Chip Stocks with Highest Dividends and 15 Best Cheap Dividend Stocks to Buy

Disclosure: None. Follow Insider Monkey on Google News.